Clinical Trials Browser

Phase 2 × Neoplasms × zanubrutinib × Clear all

NCT05681195 2026-03-03

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Phase 2 Recruiting

Neoplasms, Recurrence